GlassScriptPhysician profile
Sagar B Patel
NPI 1619382405
$87,937.92
in general payments reported to CMS, 2019-2025
17 companies · $9,240 in 2025
The $9,240 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $205 · 2021: $301 · 2022: $577 · 2023: $15K · 2024: $10K · 2025: $9,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $3,222 · Travel and Lodging: $1,487 · Honoraria: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,460.12 |
| Food and Beverage | $3,222.35 |
| Travel and Lodging | $1,487.42 |
| Honoraria | $1,390.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $51,220.32 | 2019-2023 | Eylea |
| Regeneron Healthcare Solutions, INC. | $30,142.42 | 2019-2025 | Eylea Hd, Eylea, Dupixent |
| Coherus Oncology, INC. | $1,866.93 | 2023 | |
| Alimera Sciences, INC. | $1,529.71 | 2020-2023 | Iluvien |
| Novartis Pharmaceuticals Corporation | $493.78 | 2019 | |
| Alcon Vision LLC | $472.15 | 2020-2024 | Argos, Clareon, Ngenuity |
| Boston Scientific Corporation | $465.19 | 2022-2024 | Ams 700, Spaceoar Vue System - 10ml, Spaceoar System |
| Abbvie INC. | $336.99 | 2023-2024 | |
| Astellas Pharma US INC | $297.69 | 2023-2025 | Izervay |
| Genentech USA, INC. | $294.35 | 2020-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $254.51 | 2023-2025 | Syfovre |
| US Oncology Corporate, INC. | $173.83 | 2022 | |
| Allergan, INC. | $152.21 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $136.34 | 2019 | |
| Carl Zeiss Meditec, INC. | $59.82 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $26.24 | 2019 | |
| Ocular Therapeutix, INC. | $15.44 | 2025 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sagar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.